Stereotactic body radiation therapy for metastases to the kidney in patients with non-small cell lung cancer: a new treatment paradigm for durable palliation.
Cancer metastasis to the kidney is a rare event; treatment must take into account the associated and unique anatomic and physiological challenges of treating the kidney. Stereotactic body radiation therapy (SBRT) is a widely emerging modality of radiotherapy touted for its ability to minimize irradiation to surrounding tissues and to provide a vastly shortened treatment course that is highly biologically potent. However, the use of SBRT to treat kidney neoplasms has been described in only a few case reports generally for primary renal malignancies. The role of SBRT in patients with renal metastasis, in providing durable local control and palliation of symptoms, is currently undefined. We conducted a retrospective study of patients with non-small cell lung cancer (NSCLC) and symptomatic renal metastases treated with SBRT. All patients meeting these criteria from a single institution were included. Symptomatic relief and early tumor control was achieved in all patients. We demonstrate that SBRT is a safe and effective treatment for renal metastases, with ability to spare surrounding tissues and to be delivered in a convenient treatment course of no more than 5 fractions, which lends support to its use in palliative care and appropriate oligometastatic scenarios. Further corroborative work is needed to assess kidney function after SBRT and to better characterize the expected duration of local control and palliative relief following SBRT.